MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma
- 31 January 2009
- journal article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 45 (1), 146-153
- https://doi.org/10.1016/j.ejca.2008.09.002
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastomaNeuro-Oncology, 2007
- Targeting DNA repair as a promising approach in cancer therapyEuropean Journal Of Cancer, 2007
- Aberrant Hypermethylation of p14ARF and O6‐methylguanine‐DNA Methyltransferase Genes in Astrocytoma ProgressionBrain Pathology, 2007
- A t(1;19)(q10;p10) Mediates the Combined Deletions of 1p and 19q and Predicts a Better Prognosis of Patients with OligodendrogliomaCancer Research, 2006
- Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III TrialJournal of Clinical Oncology, 2006
- Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402Journal of Clinical Oncology, 2006
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaNew England Journal of Medicine, 2005
- PTEN methylation and expression in glioblastomasActa Neuropathologica, 2003
- Inactivation of the DNA-Repair GeneMGMTand the Clinical Response of Gliomas to Alkylating AgentsNew England Journal of Medicine, 2000
- Structure, Function, and Inhibition of O6-Alkylguanine-DNA AlkyltransferaseProgress in Nucleic Acid Research and Molecular Biology, 1995